Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.

EBioMedicine - 1 Feb 2018

Röver Lea Kristin, Gevensleben Heidrun, Dietrich Jörn, Bootz Friedrich, Landsberg Jennifer, Goltz Diane, Dietrich Dimo

Abstract excerpt

Immune checkpoints are important targets for immunotherapies. However, knowledge on the epigenetic modification of immune checkpoint genes is sparse. In the present study, we investigated promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate dehydrogenase (IDH) mutations with regard to mRNA expression levels, clinicopathological parameters, previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTLA-4 Antigen
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Multivariate Analysis

Share to Neoplasm Grading

Share to Programmed Cell Death 1 Receptor

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 29396294
DOI: 10.1016/j.ebiom.2018.01.016
PMCID: PMC5835568

Genes

CTLA4
ATRX
MGMT
PDCD1
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.PMID 29396294Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma.Semantic proximity Read ↗

Correlation of immune phenotype with IDH mutation in diffuse glioma.Semantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.Semantic proximity Read ↗

Genomic Profiling of lower-grade gliomas subtype with distinct molecular and clinicopathologic characteristics via altered DNA-damage repair featuresSemantic proximity Read ↗

PD-1 related transcriptome profile and clinical outcome in diffuse gliomasSemantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

PDIA3 correlates with clinical malignant features and immune signature in human gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.